Norepinephrine and concentric hypertrophy in patients with end-stage renal disease

Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi, Saverio Parlongo, Sebastiano Cutrupi, Francesco Antonio Benedetto, Alessandro Cataliotti, Lorenzo Salvatore Malatino

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

We have recently observed that in patients with end-stage renal disease (ESRD) raised plasma norepinephrine (NE) is an independent predictor of incident cardiovascular events but that its prognostic power is reduced when this sympathetic marker is tested in statistical models including also left ventricular mass. Because left ventricular hypertrophy (LVH) may be a mechanism whereby NE contributes to the high rate of cardiovascular events in ESRD, we examined the relationship between plasma NE and echocardiographic parameters of left ventricle mass in a large group of ESRD patients. Mean wall thickness (MWT) was higher in patients in the third NE tertile than in the other 2 tertiles (P=0.001), and such an increase was paralleled by a rise in relative wall thickness (RWT) (P=0.006). Concentric LVH was more prevalent in patients in the third NE tertile (46%) than in the second (38%) and first (25%) NE tertiles. Multivariate regression analysis confirmed that the association of plasma NE with the muscular component of left ventricle (MWT) and with RWT was independent (P≤0.001) of other cardiovascular risk factors, and in these models, plasma NE ranked as the second correlate of MWT and RWT. Similarly, multiple logistic regression analysis showed that the association of plasma NE with concentric LVH was strong and again independent of other risk factors (P=0.003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalHypertension
Volume40
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Hypertrophy
Chronic Kidney Failure
Norepinephrine
Left Ventricular Hypertrophy
Heart Ventricles
Regression Analysis
Adrenergic Antagonists
Statistical Models
Adrenergic Agents
Multivariate Analysis
Logistic Models

Keywords

  • Cardiovascular risk
  • Dialysis
  • Left ventricular hypertrophy
  • Norepinephrine
  • Renal failure
  • Sympathetic activity
  • Uremia

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Zoccali, C., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Benedetto, F. A., ... Malatino, L. S. (2002). Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension, 40(1), 41-46. https://doi.org/10.1161/01.HYP.0000022063.50739.60

Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. / Zoccali, Carmine; Mallamaci, Francesca; Tripepi, Giovanni; Parlongo, Saverio; Cutrupi, Sebastiano; Benedetto, Francesco Antonio; Cataliotti, Alessandro; Malatino, Lorenzo Salvatore.

In: Hypertension, Vol. 40, No. 1, 2002, p. 41-46.

Research output: Contribution to journalArticle

Zoccali, C, Mallamaci, F, Tripepi, G, Parlongo, S, Cutrupi, S, Benedetto, FA, Cataliotti, A & Malatino, LS 2002, 'Norepinephrine and concentric hypertrophy in patients with end-stage renal disease', Hypertension, vol. 40, no. 1, pp. 41-46. https://doi.org/10.1161/01.HYP.0000022063.50739.60
Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002;40(1):41-46. https://doi.org/10.1161/01.HYP.0000022063.50739.60
Zoccali, Carmine ; Mallamaci, Francesca ; Tripepi, Giovanni ; Parlongo, Saverio ; Cutrupi, Sebastiano ; Benedetto, Francesco Antonio ; Cataliotti, Alessandro ; Malatino, Lorenzo Salvatore. / Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. In: Hypertension. 2002 ; Vol. 40, No. 1. pp. 41-46.
@article{330ce13b09214213b5937e1f0cd9682c,
title = "Norepinephrine and concentric hypertrophy in patients with end-stage renal disease",
abstract = "We have recently observed that in patients with end-stage renal disease (ESRD) raised plasma norepinephrine (NE) is an independent predictor of incident cardiovascular events but that its prognostic power is reduced when this sympathetic marker is tested in statistical models including also left ventricular mass. Because left ventricular hypertrophy (LVH) may be a mechanism whereby NE contributes to the high rate of cardiovascular events in ESRD, we examined the relationship between plasma NE and echocardiographic parameters of left ventricle mass in a large group of ESRD patients. Mean wall thickness (MWT) was higher in patients in the third NE tertile than in the other 2 tertiles (P=0.001), and such an increase was paralleled by a rise in relative wall thickness (RWT) (P=0.006). Concentric LVH was more prevalent in patients in the third NE tertile (46{\%}) than in the second (38{\%}) and first (25{\%}) NE tertiles. Multivariate regression analysis confirmed that the association of plasma NE with the muscular component of left ventricle (MWT) and with RWT was independent (P≤0.001) of other cardiovascular risk factors, and in these models, plasma NE ranked as the second correlate of MWT and RWT. Similarly, multiple logistic regression analysis showed that the association of plasma NE with concentric LVH was strong and again independent of other risk factors (P=0.003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD.",
keywords = "Cardiovascular risk, Dialysis, Left ventricular hypertrophy, Norepinephrine, Renal failure, Sympathetic activity, Uremia",
author = "Carmine Zoccali and Francesca Mallamaci and Giovanni Tripepi and Saverio Parlongo and Sebastiano Cutrupi and Benedetto, {Francesco Antonio} and Alessandro Cataliotti and Malatino, {Lorenzo Salvatore}",
year = "2002",
doi = "10.1161/01.HYP.0000022063.50739.60",
language = "English (US)",
volume = "40",
pages = "41--46",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Norepinephrine and concentric hypertrophy in patients with end-stage renal disease

AU - Zoccali, Carmine

AU - Mallamaci, Francesca

AU - Tripepi, Giovanni

AU - Parlongo, Saverio

AU - Cutrupi, Sebastiano

AU - Benedetto, Francesco Antonio

AU - Cataliotti, Alessandro

AU - Malatino, Lorenzo Salvatore

PY - 2002

Y1 - 2002

N2 - We have recently observed that in patients with end-stage renal disease (ESRD) raised plasma norepinephrine (NE) is an independent predictor of incident cardiovascular events but that its prognostic power is reduced when this sympathetic marker is tested in statistical models including also left ventricular mass. Because left ventricular hypertrophy (LVH) may be a mechanism whereby NE contributes to the high rate of cardiovascular events in ESRD, we examined the relationship between plasma NE and echocardiographic parameters of left ventricle mass in a large group of ESRD patients. Mean wall thickness (MWT) was higher in patients in the third NE tertile than in the other 2 tertiles (P=0.001), and such an increase was paralleled by a rise in relative wall thickness (RWT) (P=0.006). Concentric LVH was more prevalent in patients in the third NE tertile (46%) than in the second (38%) and first (25%) NE tertiles. Multivariate regression analysis confirmed that the association of plasma NE with the muscular component of left ventricle (MWT) and with RWT was independent (P≤0.001) of other cardiovascular risk factors, and in these models, plasma NE ranked as the second correlate of MWT and RWT. Similarly, multiple logistic regression analysis showed that the association of plasma NE with concentric LVH was strong and again independent of other risk factors (P=0.003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD.

AB - We have recently observed that in patients with end-stage renal disease (ESRD) raised plasma norepinephrine (NE) is an independent predictor of incident cardiovascular events but that its prognostic power is reduced when this sympathetic marker is tested in statistical models including also left ventricular mass. Because left ventricular hypertrophy (LVH) may be a mechanism whereby NE contributes to the high rate of cardiovascular events in ESRD, we examined the relationship between plasma NE and echocardiographic parameters of left ventricle mass in a large group of ESRD patients. Mean wall thickness (MWT) was higher in patients in the third NE tertile than in the other 2 tertiles (P=0.001), and such an increase was paralleled by a rise in relative wall thickness (RWT) (P=0.006). Concentric LVH was more prevalent in patients in the third NE tertile (46%) than in the second (38%) and first (25%) NE tertiles. Multivariate regression analysis confirmed that the association of plasma NE with the muscular component of left ventricle (MWT) and with RWT was independent (P≤0.001) of other cardiovascular risk factors, and in these models, plasma NE ranked as the second correlate of MWT and RWT. Similarly, multiple logistic regression analysis showed that the association of plasma NE with concentric LVH was strong and again independent of other risk factors (P=0.003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD.

KW - Cardiovascular risk

KW - Dialysis

KW - Left ventricular hypertrophy

KW - Norepinephrine

KW - Renal failure

KW - Sympathetic activity

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0036311224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036311224&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000022063.50739.60

DO - 10.1161/01.HYP.0000022063.50739.60

M3 - Article

VL - 40

SP - 41

EP - 46

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -